Результаты поиска

To Treat or Not to Treat: A Case of Simultaneous Discovery of Chronic Myelomonocytic Leukemia and Multiple Myeloma.

The coexistence of multiple myeloma and chronic myelomonocytic leukemia in the same patient is a rare entity. Here we describe a case of an 80-year-old man who presented to our hospital with symptoms of dyspnea and found to have anemia and leukocytosis with peripheral monocytosis. Bone marrow biopsy, flow cytometry, and fluorescence in situ hybridization studies were consistent with a laboratory diagnosis of multiple myeloma and chronic myelomonocytic leukemia. Due to advanced age and multiple comorbidities, the patient was treated conservatively. At 26 months follow-up, the patient continues

A review on how to do hematology consults during COVID-19 pandemic.

The ongoing COVID-19 pandemic is the most trending and talked topic across the World. From its point of origin in Wuhan, China to clinical laboratory at NIH, a mere six-month-old SARS-CoV-2 virus is keeping the clinicians, and scientists busy at various fronts. However, COVID-19 is an emerging and evolving disease and each day brings in more data, new figures, and findings from the field of clinical practice. The role of hematologists has been increasingly recognized during the current pandemic because of several reasons. Most important of them are the characteristic hematological findings of

Understanding Rare Anemias: Emerging Frontiers for Diagnosis and Treatment.

Background-This review provides a comprehensive overview of rare anemias, emphasizing their hereditary and acquired causes, diagnostic advancements, and evolving treatment strategies. It outlines the significance of rare anemias within public health, historical challenges in recognition and treatment, and the role of European initiatives like ENERCA and EuroBloodNet in advancing care. Content-This document discusses diagnostic technologies like next-generation sequencing and the impact of artificial intelligence, alongside the promising avenues of gene therapy, targeted drug treatments, and st

Targeting fibrosis, mechanisms and cilinical trials.

Fibrosis is characterized by the excessive extracellular matrix deposition due to dysregulated wound and connective tissue repair response. Multiple organs can develop fibrosis, including the liver, kidney, heart, and lung. Fibrosis such as liver cirrhosis, idiopathic pulmonary fibrosis, and cystic fibrosis caused substantial disease burden. Persistent abnormal activation of myofibroblasts mediated by various signals, such as transforming growth factor, platelet-derived growth factor, and fibroblast growh factor, has been recongized as a major event in the occurrence and progression of fibrosi

Совпадение в полном тексте источника
… During the study, palpable spleen length was reduced at least 50% in 70% patients receiving ruxolitinib, but 11.8% of patients needed platelet transfusion. …

Множественная миелома в West Highland White Terrier: клинические презентации и терапевтическое вмешательство.

В настоящем докладе представлен случай: seven- годовой Вест Хайленд Уайт Терриер, диагностировавший рецидив и рефрактную множественные миеломы (ММ), управлялся с использованием различных методов лечения, включая обычную химиотерапию (мельфалан, винкристин, доксорубицин и дексаметазон), радиационную терапию (РТ) и такие новые агенты, как селективный ингибитор ядерного экспорта (вердинексор), протеозные ингибиторы (бортезомиб, карфилзомиб и ixazomib) и ингибиторы тиросиновой кинезы (TKIs; тосераниб и сорафениб). Реакция на лечение отслеживалась с помощью анализа концентрации глобулина в сыворотк

Causes of Anemia in Patients Seen in a Rural Community Hematology Clinic.

IntroductionAnemia is a common medical disorder seen in consultation by hematologists. This study was performed to determine the incidence of the etiologies causing anemia in patients referred to the hematologists at Tammy Walker Cancer Center (TWCC) in the rural Kansas community of Salina. An additional goal of the study was to compare the frequencies of different etiologies for anemia in this cohort of patients with those previously reported by four academic medical centers.MethodsA retrospective review of the medical records of 152 patients seen at TWCC between August 2015 and May 2019 was

Explosive Disease Progression After Single-Agent B-cell Maturation Antigen-Targeted Treatment in Multiple Myeloma: A Report of Three Cases in Sheikh Shakhbout Medical City.

Patients with "penta-refractory" multiple myeloma (MM) are challenging to treat given the limited treatment options available to them. Belantamab mafodotin is the first B-cell maturation antigen (BCMA)-targeting antibody-drug conjugate approved for the treatment of relapsed/refractory MM (RRMM). In this case report, we reviewed in detail three female patients who were diagnosed with MM international scoring system (ISS)-3 and were heavily pretreated, and refractory to CD38 monoclonal antibodies, two proteasome inhibitors, and two immunomodulatory agents. These patients were started on belantam

Совпадение в полном тексте источника
… She completed four cycles, with frequent blood and platelet transfusion support. Her M-protein level then remained stable. In June 2022, after a multidisciplinary team discussion, they decided to treat this heavily treated RRMM with belantamab mafodotin, as it had become available in the UAE. …

History of hematopoietic cell transplantation: challenges and progress.

After more than 60 years of research in allogeneic hematopoietic cell transplantation (HCT), this therapy has advanced from one that was declared dead in the 1960s to a standard treatment of otherwise fatal malignant and non-malignant blood diseases. To date, close to 1.5 million hematopoietic cell transplants have been performed in more than 1,500 transplantation centers worldwide. This review will highlight the enormous efforts by numerous investigators throughout the world who have brought the experimental field of HCT to clinical reality, examine ongoing challenges, and provide insights fo

2020 ACVIM Forum On Demand Research Abstract Program.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Belantamab mafodotin, carfilzomib, lenalidomide и дексаметазон для рецидива или рефракта множественной миеломы.

Резюме Belantamab mafodotin (Belamaf), антитела-наркотики, направленные против антигена ячеек B-клеток, продемонстрировало активность одного агента в повторной/охлажденной миеломе (RRMM), но связано с окулярной токсичностью. Это фазы 1/2 в ходе исследования была проведена оценка безопасности и предварительной эффективности использования беналафа 8 Недели в сочетании с карфилзомидом, линалидомидом и дексаметасоном (KRd-b) у пациентов с RRMM. Пациенты, имеющие право на получение помощи, по крайней мере, 1 :: предыдущая терапия и не продвинулась по полной дозе леналидомида. На стадии " доза-

Acquired von Willebrand syndrome and lymphoproliferative disorders: A case report.

Acquired von Willebrand syndrome is a rare bleeding disorder often secondary to an underlying lymphoproliferative disorder. We report a case in whom response of both the acquired von Willebrand syndrome and smoldering multiple myeloma persist 14 months after daratumumab treatment discontinuation.

Pure red cell aplasia and minimal residual disease conversion associated with immune reconstitution in a patient with high-risk multiple myeloma.

A second bone marrow aspiration and biopsy showed pure red cell aplasia in this case.

Ten Наводки на биопсию почек у больных раком.

Ренальная биопсия — это важный диагностический инструмент, который следует учитывать у больных раком, население которого часто страдает почечной дисфункцией, многофакторной и клинической активностью. Точное выявление основных повреждений часто имеет решающее значение для руководства онкологической терапией, предотвращения дальнейшего упадка почечной железы и улучшения общих результатов. Однако проведение биопсии в этой уязвимой группе пациентов требует тщательной оценки процедурных рисков и клинического контекста. Это...10 Брошюра < < Советы > > обеспечивает практическую основу для

Carfilzomib-induced thrombotic microangiopathy (TMA) refractory to eculizumab: A case report and literature review.

This case report describes the clinical course of a patient with relapsed IgA kappa multiple myeloma with high-risk cytogenetics. Initially treated with daratumumab-bortezomib-lenalidomide-dexamethasone (Dara-VRD) then transitioned to lenalidomide maintenance. However, he experienced a relapse and was treated with carfilzomib-based therapy (CFZ) but developed drug-induced thrombotic microangiopathy (DI-TMA). Despite receiving eculizumab and supportive care, the patient's condition worsened, leading to encephalopathy and refractory gastrointestinal bleeding in the setting of persistent thromboc

Совпадение в полном тексте источника
… He continued to rely on supportive measures, including red blood cell and platelet transfusions, as well as hemodialysis. Furthermore, the upper extremities doppler ultrasound revealed acute obstructive DVT in the left axillary and brachial veins. …

Review of clinical profile and bacterial spectrum and sensitivity patterns of pathogens in febrile neutropenic patients in hematological malignancies: A retrospective analysis from a single center.

BackgroundThe aim of this study was to study clinical profile with bacterial spectrum and susceptibility patterns of pathogens in culture positive febrile neutropenic (FN) patients of hematological malignancies.Materials and methodsWe retrospectively reviewed the medical records of 23 hematological malignancy patients admitted with chemotherapy induced febrile neutropenia with culture positive results, at our institute between June 2011 and December 2011.ResultsA total of 23 patients were studied 12 males and 11 females, with a median age of 35 years. Most common diagnosis was acute leukemia (

Iron in the Tumor Microenvironment-Connecting the Dots.

Iron metabolism and tumor biology are intimately linked. Iron facilitates the production of oxygen radicals, which may either result in iron-induced cell death, ferroptosis, or contribute to mutagenicity and malignant transformation. Once transformed, malignant cells require high amounts of iron for proliferation. In addition, iron has multiple regulatory effects on the immune system, thus affecting tumor surveillance by immune cells. For these reasons, inconsiderate iron supplementation in cancer patients has the potential of worsening disease course and outcome. On the other hand, chronic im

Clinical course and end-of-life care in patients who have died after allogeneic stem cell transplantation.

PURPOSE: Allogeneic stem cell transplantation may cure approximately 50% of patients, however, a significant part of the other half might benefit from a high-quality palliative care medicine at the end of life. Somatic, psychic and spiritual needs of these patients may differ from those of patients suffering from incurable solid tumours and are not comprehensively evaluated so far. METHODS: To address this question, data from charts of 123 patients who have died after allogeneic stem cell transplantation were extracted. In detail, the time line of the clinical course, the symptoms, the admini

Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival.

BackgroundBortezomib offers a novel approach to the treatment of multiple myeloma producing rapid control. The aim of this study was to investigate the outcomes of bortezomib and dexamethasone-treated patients with multiple myeloma.MethodsWe conducted a retrospective study of 44 consecutively-treated multiple myeloma patients with bortezomib (1.3 mg/m(2) on days 1, 4, 8, and 11 of a 21-day cycle or 1.3 mg/m(2) intravenously 1, 8, 15, and 22 of every 35-day cycle) and dexamethasone.ResultsThe median time to progression, progression free survival time, and overall survival time in the treatment

Совпадение в полном тексте источника
… Patients with grade 3/4 anemia or grade 4 thrombocytopenia had blood or platelet transfusions. The most common grade 3/4 nonhematologic toxicities were tumor lysis syndrome (6.8%). No treatment-related deaths were noted. … Patients with grade 3/4 anemia or grade 4 thrombocytopenia had blood or platelet transfusions. Treatment-related deaths were not observed. Consistent with this, the first trial was reported by Richardson et al. [ 12 ], who treated 193 patients with MM with bortezomib. …

Donor Evaluation for Hematopoietic Stem and Progenitor Cell Collection

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, and Somatic (VEXAS) Syndrome: A Case Report.

VEXAS is an acronym that stands for the technical terms of key descriptors of the condition: vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic (VEXAS) syndrome, which is a recently identified autoinflammatory disorder primarily affecting men older than 50 years of age. It is commonly associated with a somatic mutation in the X-linked ubiquitin-activating enzyme-encoding UBA1 gene. This condition manifests in a range of hematologic and systemic inflammatory symptoms, such as cytopenias, recurrent fevers, and an elevated risk for hematologic malignancies like myelodysplastic syndrome